Global Ursodeoxycholic Acid Drug Product Revenue Is About 970 Million USD In 2017
Warning: date() expects parameter 2 to be long, string given in /www/wwwroot/www.globalinforesearch.com/static/themes/default/info_detail.php on line 32
In the last several years, global market of Ursodeoxycholic Acid Drug Product developed rapidly, with an average growth rate of 11.9%. In 2017, global revenue of Ursodeoxycholic Acid Drug Product is about 970 million USD.
The classification of Ursodeoxycholic Acid Drug Product includes Capsule and Tablet. And the proportion of Capsule in 2017 is about 94.8%, and the proportion is in decreasing trend from 2013 to 2018, In China, the major product is tablet, and with low concentration UDCA, and the price is also low than other manufacturers. The major products of Dr. Falk Pharma, Daewoong Pharmaceutical, Teva are capsule.
Ursodeoxycholic Acid Drug Product can be applied in Gallstone, Hepatopathy, Biliary Disease and Other. The most of Ursodeoxycholic Acid Drug Product is used in Gallstone, and the market share of that is about 36.5% in 2017.
North America is the largest sales place, with a sales market share nearly 30% in 2017. Following North America, Europe is the second largest sales place with the Sales market share of 22.1%. Ursodeoxycholic Acid Drug Product market in Asia Pacific region is expected to exhibit the highest growth rate especially in the developing Asian countries like China & India.
Dr. Falk Pharma, Daewoong Pharmaceutical, Teva, etc. are the global leading manufactures in the world. In the future, more generic manufacturers will enter into this industry.
In North America, Epic Pharma is leading manufacturers, Teva, Lannett and Mylan are major suppliers of Ursodeoxycholic Acid Drug Product in USA market. In China, Dr. Falk Pharma is leading manufacturers, the market share is about 81% in 2017. In Japan, Mitsubishi Tanabe Pharma?is leading manufacturers, the market share is about 52% in 2017. In Korea, Daewoong Pharmaceutical is leading manufacturers, the market share is about 86.1% in 2017